Refine
Document Type
Is part of the Bibliography
- yes (42)
Keywords
- Cardiac rehabilitation (7)
- cardiac rehabilitation (7)
- Return to work (5)
- Frailty (3)
- TAVI (3)
- chronic kidney disease (3)
- genetics (3)
- hypertension (3)
- myocardial infarction (3)
- patient education (3)
- physical activity (3)
- rehabilitation (3)
- return to work (3)
- Acute coronary syndrome (2)
- Geriatric rehabilitation (2)
- Treatment pathways (2)
- acute coronary event (2)
- cardiorespiratory fitness (2)
- clinical study (2)
- cognitive impairment (2)
- control rates (2)
- cytochrome P450 17A1 (Cyp17A1) (2)
- dyslipidemia (2)
- endomyocardial biopsy (2)
- exercise tests (2)
- glomerular filtration rate (2)
- healthy lifestyle (2)
- heart (2)
- lipids (2)
- multivariate modelling (2)
- myocarditis (2)
- negative expectation (2)
- occupational prognosis (2)
- pension insurance (2)
- prediction (2)
- predictors (2)
- prevalence (2)
- primary prevention (2)
- registry (2)
- risk factor (2)
- telemedicine (2)
- work capacity (2)
- Acute myocardial infarction (1)
- Arterial hypertension (1)
- Cardiac rehabilitation Chronic heart failure (1)
- Cardiovascular disease (1)
- Clinical study (1)
- Control rates (1)
- Coronary artery bypass grafting (1)
- Coronary disease (1)
- Dyslipidemia (1)
- Ergebnisqualität (1)
- Exercise capacity (1)
- Expertenbefragung (1)
- Genetics (1)
- Glomerular filtration rate (1)
- Heart (1)
- Herzinfarkt (1)
- Hypertension (1)
- Lebensstil (1)
- Left ventricular hypertrophy (1)
- Lipid profile (1)
- Malnutrition (1)
- Melatonin receptor type 2 (1)
- Mild cognitive impairment (1)
- Mobility (1)
- Mortality (1)
- Motivation (1)
- Observational (1)
- Prognosis (1)
- Prospective study (1)
- Prädiktoren (1)
- Prävention (1)
- Quality of life (1)
- Qualitätsindikatoren (1)
- RCT (1)
- Rehabilitation (1)
- Rehabilitationserfolg (1)
- Rentenversicherung (1)
- Risk factor (1)
- Social medicine (1)
- Social work (1)
- Tamm-Horsfall protein (1)
- acute coronary syndrome (1)
- berufliche Wiedereingliederung (1)
- blood pressure (1)
- cardiovascular complications (1)
- cardioverter-defibrillator (1)
- coronary artery disease (1)
- digital health (1)
- digitale Gesundheit (1)
- disease severity (1)
- exercise stress test (1)
- exercise training (1)
- expert survey (1)
- federal states (1)
- hamburger model (1)
- heart failure (1)
- hospital mortality (1)
- kardiologische Rehabilitation (1)
- kidney function (1)
- körperliche Aktivität (1)
- lifestyle (1)
- mHealth (1)
- mobile Assistenzsysteme (1)
- multimodal cardiac rehabilitation (1)
- northeast of Germany (1)
- organ damage (1)
- outcome (1)
- performance measures (1)
- prevention (1)
- quality assurance (1)
- regression toward the mean (1)
- rehabilitation outcome (1)
- secondary data analysis (1)
- secondary prevention (1)
- statutory health insurance (1)
- therapy volume (1)
- training and decision support system (1)
Cytochrome P450 17A1 (CYP17A1) catalyses the formation and metabolism of steroid hormones. They are involved in blood pressure (BP) regulation and in the pathogenesis of left ventricular hypertrophy. Therefore, altered function of CYP17A1 due to genetic variants may influence BP and left ventricular mass. Notably, genome wide association studies supported the role of this enzyme in BP control. Against this background, we investigated associations between single nucleotide polymorphisms (SNPs) in or nearby the CYP17A1 gene with BP and left ventricular mass in patients with arterial hypertension and associated cardiovascular organ damage treated according to guidelines. Patients (n = 1007, mean age 58.0 +/- 9.8 years, 83% men) with arterial hypertension and cardiac left ventricular ejection fraction (LVEF) 40% were enrolled in the study. Cardiac parameters of left ventricular mass, geometry and function were determined by echocardiography. The cohort comprised patients with coronary heart disease (n = 823; 81.7%) and myocardial infarction (n = 545; 54.1%) with a mean LVEF of 59.9% +/- 9.3%. The mean left ventricular mass index (LVMI) was 52.1 +/- 21.2 g/m(2.7) and 485 (48.2%) patients had left ventricular hypertrophy. There was no significant association of any investigated SNP (rs619824, rs743572, rs1004467, rs11191548, rs17115100) with mean 24 h systolic or diastolic BP. However, carriers of the rs11191548 C allele demonstrated a 7% increase in LVMI (95% CI: 1%-12%, p = 0.017) compared to non-carriers. The CYP17A1 polymorphism rs11191548 demonstrated a significant association with LVMI in patients with arterial hypertension and preserved LVEF. Thus, CYP17A1 may contribute to cardiac hypertrophy in this clinical condition.
Cytochrome P450 17A1 (CYP17A1) catalyses the formation and metabolism of steroid hormones. They are involved in blood pressure (BP) regulation and in the pathogenesis of left ventricular hypertrophy. Therefore, altered function of CYP17A1 due to genetic variants may influence BP and left ventricular mass. Notably, genome wide association studies supported the role of this enzyme in BP control. Against this background, we investigated associations between single nucleotide polymorphisms (SNPs) in or nearby the CYP17A1 gene with BP and left ventricular mass in patients with arterial hypertension and associated cardiovascular organ damage treated according to guidelines. Patients (n = 1007, mean age 58.0 ± 9.8 years, 83% men) with arterial hypertension and cardiac left ventricular ejection fraction (LVEF) ≥40% were enrolled in the study. Cardiac parameters of left ventricular mass, geometry and function were determined by echocardiography. The cohort comprised patients with coronary heart disease (n = 823; 81.7%) and myocardial infarction (n = 545; 54.1%) with a mean LVEF of 59.9% ± 9.3%. The mean left ventricular mass index (LVMI) was 52.1 ± 21.2 g/m2.7 and 485 (48.2%) patients had left ventricular hypertrophy. There was no significant association of any investigated SNP (rs619824, rs743572, rs1004467, rs11191548, rs17115100) with mean 24 h systolic or diastolic BP. However, carriers of the rs11191548 C allele demonstrated a 7% increase in LVMI (95% CI: 1%–12%, p = 0.017) compared to non-carriers. The CYP17A1 polymorphism rs11191548 demonstrated a significant association with LVMI in patients with arterial hypertension and preserved LVEF. Thus, CYP17A1 may contribute to cardiac hypertrophy in this clinical condition.